Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report

We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance statu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Luigi, Cimino, Giuseppe, Gozzi, Elisa, Sinjari, Marsela, Brandi, Martina, Ceddia, Serena, Cosimati, Antonella, Raimondi, Lucrezia, Fontana, Antonella, Filippi, Luca, Bagni, Oreste, Spinelli, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077606/
https://www.ncbi.nlm.nih.gov/pubmed/33976646
http://dx.doi.org/10.1159/000514979
Descripción
Sumario:We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide.

Ejemplares similares